Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the DNA Repair Pathway in Ewing Sarcoma

24 Oct 2014

Abstract excerpt

Ewing sarcoma (EWS) is a tumor of the bone and soft tissue that primarily affects adolescents and young adults. With current therapies, 70% of patients with localized disease survive, but patients with metastatic or recurrent disease have a poor outcome. We found that EWS cell lines are defective in DNA break repair and are sensitive to PARP inhibitors (PARPis). PARPi-induced cytotoxicity in EWS cells was 10- to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25437539
DOI: 10.1016/j.celrep.2014.09.028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the DNA Repair Pathway in Ewing SarcomaPMID 25437539Read ↗

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s SarcomaSemantic proximity Read ↗

Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing SarcomaSemantic proximity Read ↗

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedinSemantic proximity Read ↗

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task ForceSemantic proximity Read ↗

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.Semantic proximity Read ↗

Efficacy of ATR inhibitors as single agents in Ewing sarcomaSemantic proximity Read ↗

Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2Semantic proximity Read ↗

Targeting the p53 pathway to treat Malignant Rhabdoid and Atypical Teratoid Rhabdoid TumorsSemantic proximity Read ↗

PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathwaysSemantic proximity Read ↗

Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma CellsSemantic proximity Read ↗

A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcomaSemantic proximity Read ↗

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway SignalingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.